Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

71
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
71
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

129
Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
129
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

94
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
94
Diabetes Mellitus: Type 2 and Gestational01:22

Diabetes Mellitus: Type 2 and Gestational

5.9K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
5.9K
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters01:16

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

158
The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...
158
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.9K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Corrigendum] Associations between Huwe1 and autophagy in rat cerebral neuron oxygen‑glucose deprivation and reperfusion injury.

Molecular medicine reports·2026
Same author

[Corrigendum] p57<sup>KIP2</sup>‑mediated inhibition of human trophoblast apoptosis and promotion of invasion <i>in vitro</i>.

International journal of molecular medicine·2026
Same author

Correction: The promoter T-413A variant and elevated enzyme levels of heme oxygenase-1 associated with an increased risk of polycystic ovarian syndrome.

Frontiers in endocrinology·2026
Same author

Apolipoprotein C1 -317H1/H2 and the rs4420638 genetic variations and risk of gestational diabetes mellitus in Chinese women: a case-control study.

Frontiers in endocrinology·2025
Same author

GLIS3 rs7034200 and ADRB3 rs4994 genetic variants associated with an increased risk of gestational diabetes mellitus in Chinese women: a case-control study.

BMC pregnancy and childbirth·2025
Same author

The promoter T-413A variant and elevated enzyme levels of heme oxygenase-1 associated with an increased risk of polycystic ovarian syndrome.

Frontiers in endocrinology·2025

Related Experiment Video

Updated: Apr 15, 2026

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

35.1K

[Interaction between GNB3 C825T and ACE I/D polymorphisms in pre-eclampsia].

Lei Ma, Ping Fan, Xing-hui Liu

    Sichuan Da Xue Xue Bao. Yi Xue Ban = Journal of Sichuan University. Medical Science Edition
    |March 27, 2015
    PubMed
    Summary
    This summary is machine-generated.

    This study found no significant link between G protein beta3 subunit (GNB3) and angiotensin-I converting enzyme (ACE) gene variants and pre-eclampsia risk. However, these gene variants did affect diastolic blood pressure in women without pre-eclampsia.

    More Related Videos

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
    07:00

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

    Published on: April 1, 2019

    10.6K

    Related Experiment Videos

    Last Updated: Apr 15, 2026

    Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
    09:34

    Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

    Published on: April 4, 2018

    35.1K
    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene
    07:00

    A Method to Study the C924T Polymorphism of the Thromboxane A2 Receptor Gene

    Published on: April 1, 2019

    10.6K

    Area of Science:

    • Genetics
    • Obstetrics
    • Cardiovascular Physiology

    Background:

    • Pre-eclampsia is a pregnancy complication with complex genetic factors.
    • The G protein beta3 subunit (GNB3) C825T polymorphism and angiotensin-I converting enzyme (ACE) insertion/deletion (I/D) polymorphism are candidate genes for cardiovascular and pregnancy disorders.

    Purpose of the Study:

    • To investigate the potential interaction between GNB3 C825T and ACE I/D polymorphisms and their association with pre-eclampsia risk.
    • To explore the influence of these gene variants on blood pressure levels during pregnancy.

    Main Methods:

    • Genotyping for GNB3 C825T and ACE I/D polymorphisms was performed using polymerase chain reaction (PCR) and PCR-restriction fragment length polymorphism.
    • The study included 188 pre-eclamptic patients and 273 healthy pregnant controls from the Chinese population in Chengdu.
    • Statistical analyses were conducted to assess genotype distributions, allele frequencies, and their association with pre-eclampsia and blood pressure.

    Main Results:

    • No significant association was found between GNB3 C825T or ACE I/D polymorphisms and the risk of pre-eclampsia.
    • No significant interaction between GNB3 and ACE genotypes was observed regarding pre-eclampsia risk.
    • In non-preeclamptic controls, carriers of the homozygous GNB3 825TT genotype with the ACE II genotype exhibited the highest diastolic blood pressure (DBP) levels.

    Conclusions:

    • The study suggests no significant interaction between GNB3 825T allele carriers and ACE I/D polymorphism in the development of pre-eclampsia in the studied Chinese population.
    • An interaction between GNB3 and ACE genotypes was identified, influencing diastolic blood pressure in pregnant women without pre-eclampsia.